1. HBW Insight
  2. >>Digital Technologies

When Using Artificial Intelligence In Pharma R&D, Start With Identifying Problem To Solve

 
• By Malcolm Spicer

VeriSIM uses generative AI for questions such as changing a drug molecule’s chemistry and machine learning to better predict potential biological implications. “When a child is learning a language, you're teaching a child starting from A-to-Z structures, and then suddenly they start speaking. Then they start learning different things, and then they get into problem solving. That's really what AI is getting really good at now,” says CEO Jo Varshney.

VeriSIM Life's BioSIM “virtual drug development engine” narrows the number of drug compounds that offer anticipated value for the treatment or cure of specific illness or disease. • Source: VeriSIM Life

Artificial intelligence can provide paths for pharmaceutical firms to cut costs and time for getting additional OTC as well as Rx drugs to market. Their first step, says the CEO of a pharmaceutical AI developer, is determining the questions they need to answer.

“I ask people, what is the problem that you want me to solve instead of what kind of AI do you want to use? It's a simple change in the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Digital Technologies

More from HBW Insight

Galenica’s Verfora Gets Off To Flying Start In Swiss CHC Market

 
• By Tom Gallen

Verfora grows almost 10-times faster than the Swiss consumer health market in the opening months of 2025.

Review Suggests Advantage Of Bayer’s Iberogast Advance For Digestive Disorders

 
• By David Ridley

Bayer's Iberogast Advance's combination of six herbal ingredients may produce a synergistic effect that acts on multiple underlying issues contributing to digestive disorders like functional dyspepsia (FD) and irritable bowel syndrome (IBS), a recently published study suggests.

E.l.f. Plans To Acquire Hailey Bieber Beauty Brand For $1Bn

 
• By Eileen Francis

E.l.f. Beauty, Inc. has agreed to acquire celebrity and model Hailey Bieber’s rhode lifestyle beauty brand for $1bn, the firm reported during a 28 May fiscal fourth quarter earnings call, during which it also announced plans to raise product prices to ‘partially’ mitigate the impact of tariffs.